Did you mean 502 2,3 6?
Displaying drugs 5626 - 5650 of 9154 in total
EVT 201
EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.
Investigational
Matched Iupac: … 11-chloro-5-{5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl}-8-methyl-2,4,8-triazatricyclo[8.4.0.0^{2,6 …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
ALKS 29
ALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.
Investigational
GEM-231
GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase. A monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types...
Investigational
DDP-200
DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.
Investigational
AMG-222
Investigational
Matched Iupac: … 1,2,3,4-tetrazol-5-yl)tricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaene-6,13-dicarboxamide ... 2-[(2S)-2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)propyl]-N6,N6,N13,N13-tetramethyl-2-(2H- …
TAK-243
TAK-243 is under investigation in clinical trial NCT03816319 (TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia).
Investigational
Matched Iupac: … [(1R,2R,3S,4R)-2,3-dihydroxy-4-[(2-{3-[(trifluoromethyl)sulfanyl]phenyl}pyrazolo[1,5-a]pyrimidin-7-yl …
MK-2748
MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).
Investigational
Matched Iupac: … (1R,18R,22R,26S,29S)-26-cyclopentyl-N-[(1R,2S)-2-ethenyl-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl} …
PT-2385
PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).
Investigational
Matched Iupac: … 3-{[(1S)-2,2-difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1H-inden-4-yl]oxy}-5-fluorobenzonitrile …
SRX-246
Investigational
Matched Synonyms: … .-((3s,4r)-2-oxo-3-((4s)-2-oxo-4-phenyl-3-oxazolidinyl)-4-((1e)-2-phenylethenyl)-1-azetidinyl)-n-((1r ... .-((3s,4r)-2-oxo-3-((4s)-2-oxo-4-phenyl-3-oxazolidinyl)-4-((1e)-2-phenylethenyl)-1-azetidinyl)-n-((1r ... .-((3s,4r)-2-oxo-3-((4s)-2-oxo-4-phenyl-3-oxazolidinyl)-4-((1e)-2-phenylethenyl)-1-azetidinyl)-n-((1r …
Matched Iupac: … (2R)-4-{[1,4'-bipiperidin]-1'-yl}-4-oxo-2-[(3S,4R)-2-oxo-3-[(4S)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]- ... 4-[(1E)-2-phenylethenyl]azetidin-1-yl]-N-[(1R)-1-phenylethyl]butanamide …
Matched Iupac: … (2R)-4-{[1,4'-bipiperidin]-1'-yl}-4-oxo-2-[(3S,4R)-2-oxo-3-[(4S)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]- ... 4-[(1E)-2-phenylethenyl]azetidin-1-yl]-N-[(1R)-1-phenylethyl]butanamide …
LP-2307
LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.
Investigational
OCE-205
Investigational
ABO-201
Investigational
LYT-200
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
EDI-200
EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
Investigational
MK-2225
Investigational
HMI-204
HMI-204 is an adeno-associated virus serotype HSC15 expressing human arylsulfatase A
Investigational
RGX-202
RGX-202 is a recombinant AAV8 that contains a vector genome encoding a miniaturized dystrophin protein (microdystrophin).
Investigational
TRK-250
TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.
Investigational
3,6,9,12,15-Pentaoxaheptadecane
Experimental
(2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID
Experimental
Matched Name: … (2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID …
Matched Iupac: … (2E)-3-[2-(oct-1-yn-1-yl)phenyl]prop-2-enoic acid …
Matched Iupac: … (2E)-3-[2-(oct-1-yn-1-yl)phenyl]prop-2-enoic acid …
1-Naphthylamine-5-sulfonic acid
Experimental
Matched Synonyms: … 1-Amino-5-sulfonaphthalene ... 1-Amino-5-naphthalenesufonic acid ... 5-Naphthylamine-1-sulfonic acid …
Matched Name: … 1-Naphthylamine-5-sulfonic acid …
Matched Iupac: … 5-aminonaphthalene-1-sulfonic acid …
Matched Name: … 1-Naphthylamine-5-sulfonic acid …
Matched Iupac: … 5-aminonaphthalene-1-sulfonic acid …
JE-2147
Experimental
Matched Iupac: … (4R)-3-[(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-phenylbutanoyl]-5,5-dimethyl-N-[( ... 2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide …
ATX-201
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
Displaying drugs 5626 - 5650 of 9154 in total